Novel taxane formulations in the treatment of breast cancer

A thought leader discussion and consensus roundtable

Julie Gralow, Hope Rugo, William Gradishar, Joyce A. O'Shaughnessy, Mohammed Jahanzeb, Edith Perez, Debu Tripathy

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Many chemotherapeutic and biologic agents used for advanced breast cancer exhibit activity alone or in combination, but the small number of randomized trials, coupled with the significant heterogeneity of patient and tumor characteristics, have precluded the development of standardized, evidence-based approaches to therapy for advanced disease. This expert faculty roundtable discussion focused on chemotherapy regimens used in pretreated patients. Given the increasing data on taxanes in this setting, a specific need was identified that led to the theme of standard and novel taxanes in this discussion. Numerous factors can predict response and long-term outcome: tumor characteristics like hormone and HER2 receptor status and grade and clinical characteristics like age, functional status, disease-free interval, previous adjuvant therapy, and sites or burden of metastatic disease. The choice of therapeutic agents or combinations, therefore, relies not only on randomized or phase II trial results but also on patient context in relation to these variables. After anthracycline and taxane therapy, agents such as capecitabine, vinorelbine, gemcitabine, and platinum agents and combinations thereof can be active. Taxanes themselves also possess activity, with a dependency on a specific agent and schedule. Albumin-bound paclitaxet has demonstrated superiority to certain taxane agents and schedules and has demonstrated activity after taxane exposure. This discussion highlights basic paradigms by which standard taxanes and albumin-bound paclitaxel can be evaluated as possible therapeutic or investigative options, along with nontaxane agents, emerging biologic agents, and combinations.

Original languageEnglish (US)
Pages (from-to)33-37
Number of pages5
JournalClinical Breast Cancer
Volume8
Issue number1
DOIs
StatePublished - 2008

Fingerprint

Taxoids
Breast Neoplasms
Biological Factors
gemcitabine
Appointments and Schedules
Therapeutics
Anthracyclines
Platinum
Albumins
Neoplasms
taxane
Hormones
Drug Therapy

Keywords

  • Albumin-bound paclitaxel
  • Capecitabine
  • Docetaxel
  • Gemcitabine
  • Metastatic disease

ASJC Scopus subject areas

  • Cancer Research

Cite this

Gralow, J., Rugo, H., Gradishar, W., O'Shaughnessy, J. A., Jahanzeb, M., Perez, E., & Tripathy, D. (2008). Novel taxane formulations in the treatment of breast cancer: A thought leader discussion and consensus roundtable. Clinical Breast Cancer, 8(1), 33-37. https://doi.org/10.3816/CBC.2008.n.046

Novel taxane formulations in the treatment of breast cancer : A thought leader discussion and consensus roundtable. / Gralow, Julie; Rugo, Hope; Gradishar, William; O'Shaughnessy, Joyce A.; Jahanzeb, Mohammed; Perez, Edith; Tripathy, Debu.

In: Clinical Breast Cancer, Vol. 8, No. 1, 2008, p. 33-37.

Research output: Contribution to journalArticle

Gralow, J, Rugo, H, Gradishar, W, O'Shaughnessy, JA, Jahanzeb, M, Perez, E & Tripathy, D 2008, 'Novel taxane formulations in the treatment of breast cancer: A thought leader discussion and consensus roundtable', Clinical Breast Cancer, vol. 8, no. 1, pp. 33-37. https://doi.org/10.3816/CBC.2008.n.046
Gralow, Julie ; Rugo, Hope ; Gradishar, William ; O'Shaughnessy, Joyce A. ; Jahanzeb, Mohammed ; Perez, Edith ; Tripathy, Debu. / Novel taxane formulations in the treatment of breast cancer : A thought leader discussion and consensus roundtable. In: Clinical Breast Cancer. 2008 ; Vol. 8, No. 1. pp. 33-37.
@article{e25d56c278b245f5a6097aa34bd8f0fb,
title = "Novel taxane formulations in the treatment of breast cancer: A thought leader discussion and consensus roundtable",
abstract = "Many chemotherapeutic and biologic agents used for advanced breast cancer exhibit activity alone or in combination, but the small number of randomized trials, coupled with the significant heterogeneity of patient and tumor characteristics, have precluded the development of standardized, evidence-based approaches to therapy for advanced disease. This expert faculty roundtable discussion focused on chemotherapy regimens used in pretreated patients. Given the increasing data on taxanes in this setting, a specific need was identified that led to the theme of standard and novel taxanes in this discussion. Numerous factors can predict response and long-term outcome: tumor characteristics like hormone and HER2 receptor status and grade and clinical characteristics like age, functional status, disease-free interval, previous adjuvant therapy, and sites or burden of metastatic disease. The choice of therapeutic agents or combinations, therefore, relies not only on randomized or phase II trial results but also on patient context in relation to these variables. After anthracycline and taxane therapy, agents such as capecitabine, vinorelbine, gemcitabine, and platinum agents and combinations thereof can be active. Taxanes themselves also possess activity, with a dependency on a specific agent and schedule. Albumin-bound paclitaxet has demonstrated superiority to certain taxane agents and schedules and has demonstrated activity after taxane exposure. This discussion highlights basic paradigms by which standard taxanes and albumin-bound paclitaxel can be evaluated as possible therapeutic or investigative options, along with nontaxane agents, emerging biologic agents, and combinations.",
keywords = "Albumin-bound paclitaxel, Capecitabine, Docetaxel, Gemcitabine, Metastatic disease",
author = "Julie Gralow and Hope Rugo and William Gradishar and O'Shaughnessy, {Joyce A.} and Mohammed Jahanzeb and Edith Perez and Debu Tripathy",
year = "2008",
doi = "10.3816/CBC.2008.n.046",
language = "English (US)",
volume = "8",
pages = "33--37",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Novel taxane formulations in the treatment of breast cancer

T2 - A thought leader discussion and consensus roundtable

AU - Gralow, Julie

AU - Rugo, Hope

AU - Gradishar, William

AU - O'Shaughnessy, Joyce A.

AU - Jahanzeb, Mohammed

AU - Perez, Edith

AU - Tripathy, Debu

PY - 2008

Y1 - 2008

N2 - Many chemotherapeutic and biologic agents used for advanced breast cancer exhibit activity alone or in combination, but the small number of randomized trials, coupled with the significant heterogeneity of patient and tumor characteristics, have precluded the development of standardized, evidence-based approaches to therapy for advanced disease. This expert faculty roundtable discussion focused on chemotherapy regimens used in pretreated patients. Given the increasing data on taxanes in this setting, a specific need was identified that led to the theme of standard and novel taxanes in this discussion. Numerous factors can predict response and long-term outcome: tumor characteristics like hormone and HER2 receptor status and grade and clinical characteristics like age, functional status, disease-free interval, previous adjuvant therapy, and sites or burden of metastatic disease. The choice of therapeutic agents or combinations, therefore, relies not only on randomized or phase II trial results but also on patient context in relation to these variables. After anthracycline and taxane therapy, agents such as capecitabine, vinorelbine, gemcitabine, and platinum agents and combinations thereof can be active. Taxanes themselves also possess activity, with a dependency on a specific agent and schedule. Albumin-bound paclitaxet has demonstrated superiority to certain taxane agents and schedules and has demonstrated activity after taxane exposure. This discussion highlights basic paradigms by which standard taxanes and albumin-bound paclitaxel can be evaluated as possible therapeutic or investigative options, along with nontaxane agents, emerging biologic agents, and combinations.

AB - Many chemotherapeutic and biologic agents used for advanced breast cancer exhibit activity alone or in combination, but the small number of randomized trials, coupled with the significant heterogeneity of patient and tumor characteristics, have precluded the development of standardized, evidence-based approaches to therapy for advanced disease. This expert faculty roundtable discussion focused on chemotherapy regimens used in pretreated patients. Given the increasing data on taxanes in this setting, a specific need was identified that led to the theme of standard and novel taxanes in this discussion. Numerous factors can predict response and long-term outcome: tumor characteristics like hormone and HER2 receptor status and grade and clinical characteristics like age, functional status, disease-free interval, previous adjuvant therapy, and sites or burden of metastatic disease. The choice of therapeutic agents or combinations, therefore, relies not only on randomized or phase II trial results but also on patient context in relation to these variables. After anthracycline and taxane therapy, agents such as capecitabine, vinorelbine, gemcitabine, and platinum agents and combinations thereof can be active. Taxanes themselves also possess activity, with a dependency on a specific agent and schedule. Albumin-bound paclitaxet has demonstrated superiority to certain taxane agents and schedules and has demonstrated activity after taxane exposure. This discussion highlights basic paradigms by which standard taxanes and albumin-bound paclitaxel can be evaluated as possible therapeutic or investigative options, along with nontaxane agents, emerging biologic agents, and combinations.

KW - Albumin-bound paclitaxel

KW - Capecitabine

KW - Docetaxel

KW - Gemcitabine

KW - Metastatic disease

UR - http://www.scopus.com/inward/record.url?scp=40449109379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449109379&partnerID=8YFLogxK

U2 - 10.3816/CBC.2008.n.046

DO - 10.3816/CBC.2008.n.046

M3 - Article

VL - 8

SP - 33

EP - 37

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -